Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer
NCT ID: NCT00900133
Last Updated: 2015-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2005-01-31
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This laboratory study is measuring calgranulin A and calgranulin B levels in the blood of patients with newly diagnosed stage I, stage II, or stage III breast cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer
NCT00898703
Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer
NCT00897416
Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease
NCT00813878
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
NCT01000883
Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer
NCT00897208
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine circulating levels of calgranulin A and calgranulin B in patients with estrogen receptor negative or estrogen receptor positive, newly diagnosed, primary stage I-III adenocarcinoma of the breast.
OUTLINE: This is a pilot study.
Patients undergo a blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B. Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
immunoenzyme technique
Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
laboratory biomarker analysis
Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed primary adenocarcinoma of the breast
* Stage I-III disease
* No evidence of metastatic disease
* Newly diagnosed disease
* Hormone receptor status:
* Estrogen receptor-positive- or -negative tumor
PATIENT CHARACTERISTICS:
Sex
* Not specified
Menopausal status
* Not specified
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
Other
* Not pregnant
* No Crohn's disease
* No arthritis
* No psoriasis
* No lupus erythematosus
* No multiple sclerosis
* No other severe active inflammation
* Not C-reactive protein positive
* No HIV positivity
* No other serious medical or psychiatric illness
PRIOR CONCURRENT THERAPY:
Radiotherapy
* No prior radiotherapy for breast cancer
Surgery
* No prior organ transplantation
Other
* No prior systemic therapy for breast cancer
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Case Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Pink, PhD
Role: PRINCIPAL_INVESTIGATOR
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CASE-7104
Identifier Type: OTHER
Identifier Source: secondary_id
CASE7104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.